ER‑100 (Life Biosciences): partial epigenetic reprogramming therapy for optic neuropathies

Daniel Platteau

What is ER‑100?

ER‑100 is an investigational gene therapy developed by Life Biosciences to treat age-related optic neuropathies, specifically open‑angle glaucoma (OAG) and non‑arteritic anterior ischemic optic neuropathy (NAION)[1][3][4].
It aims to rejuvenate retinal ganglion cells (RGCs) through partial epigenetic reprogramming rather than by replacing a mutated gene[1][4][9].

The therapy uses a modified adeno‑associated virus (AAV) vector to deliver three transcription factors – OCT4, SOX2, and KLF4 (OSK) – to retinal cells, based on the Yamanaka factors but without c‑MYC to reduce oncogenic risk[3][4][9].
OSK expression is controlled by oral doxycycline for about 8 weeks, allowing reversible activation and deactivation of the reprogramming program[3][5][9].

Scientific background: from Yamanaka factors to retinal reprogramming

Shinya Yamanaka’s pioneering work showed that somatic cells can be reprogrammed into induced pluripotent stem cells by expressing four factors (OCT4, SOX2, KLF4, c‑MYC), highlighting the central role of epigenetic marks in cell identity[9].
Building on this, several groups – notably David Sinclair’s lab at Harvard – explored partial epigenetic reprogramming, i.e. transient activation of some of these factors to rejuvenate cells without driving them back to full pluripotency[4][9].

In a landmark study, controlled expression of OSK in RGCs of mice led to restored visual function and axon regeneration in models of optic nerve injury, glaucoma, and aging[4][9].
Epigenetic clock analyses showed partial reversal of DNA methylation age and a shift toward younger gene expression profiles in these neurons[4][9].

Life Biosciences built on these findings to create its Partial Epigenetic Reprogramming (PER) platform, with ER‑100 as its first clinical-stage candidate[1][4][7].
The company positions itself in the field of longevity medicine, targeting aging mechanisms at the transcriptional level rather than treating isolated symptoms[1][4][7].

Mechanism of action

ER‑100 is best described as an epigenetic therapy: its goal is to reset specific epigenetic marks in RGCs, restoring gene expression programs characteristic of younger, healthier cells[3][4][9].

Key design features:

Modified AAV vector: delivers OSK genes to retinal cells while being engineered to remove its ability to cause infectious disease[3][9].
Targeting retinal ganglion cells: AAV serotype, promoter choice, and intravitreal delivery are tuned to favor expression in RGCs, the neurons that form the optic nerve[3][4][10].
Doxycycline‑inducible system: OSK expression is switched on by oral doxycycline for 56 days (8 weeks) and then progressively silenced when doxycycline is stopped[3][5][9].

The central idea is to provide a “controlled rejuvenation pulse”: during the activation window, RGCs adjust their epigenome and potentially regain resilience, repair capacity, and improved signal transmission.
After the window closes, neurons remain differentiated but (ideally) with improved function[4][9].

Preclinical data: mice and non‑human primates

Mouse models

In mouse models of optic nerve crush, experimental glaucoma, and aging, OSK expression via AAV resulted in:

axon regeneration of retinal ganglion cells, previously considered non‑regenerative in adults;
improved functional readouts of vision (behavioral assays, ERG);
partial reversal of epigenetic age as measured by DNA methylation clocks and transcriptional profiling[4][9].

These studies provided the core scientific rationale for ER‑100, showing that post‑mitotic neurons can be rejuvenated without full dedifferentiation[4][9].

Non‑human primate models

Life Biosciences then tested ER‑100 in non‑human primates using a NAION‑like model.
A single intravitreal injection of ER‑100 plus daily doxycycline led to:

reduced functional deficits in RGCs measured by pattern ERG;
preservation of higher axon density in the optic nerve;
detectable OSK expression in perifoveal retinal cells[10].

Within the studied timeframe, no clear increase in tumor formation or loss of cell identity was reported, which was critical for obtaining FDA approval for a first‑in‑human trial[3][10].

Together, these data suggest that partial epigenetic reprogramming can restore function in vulnerable neurons like RGCs in a controlled experimental setting[4][9][10].

Phase 1 clinical trial: design and goals

IND clearance and trial launch

On January 28, 2026, the FDA granted IND clearance for ER‑100, allowing Life Biosciences to start a Phase 1 trial in patients with OAG and NAION[1][7][9].
The study, registered as NCT07290244, is described as the first human trial of partial epigenetic reprogramming for an age‑related disease[1][4][9].

According to public information, the trial:

is a first‑in‑human Phase 1 study primarily focused on safety and tolerability of a single dose;
enrolls adults 40–85 years old with OAG or NAION[3][4];
plans up to 18 participants in sequential cohorts (OAG first, NAION later)[2][5].

In June 2026, Life Biosciences announced that the first patient had been dosed, marking the clinical debut of ER‑100[2][5][8].

Dosing regimen

Single intravitreal injection of ER‑100 in one eye[3][4].
Oral doxycycline for 56 days to activate OSK expression during this window[3][5].
No further dosing thereafter, but long‑term follow‑up up to 5 years to monitor safety and durability[3][4].

Primary and exploratory endpoints

Primary endpoints:

assessment of safety (adverse events, ocular inflammation, immune responses) and tolerability in OAG/NAION patients[1][3][7].

Exploratory endpoints:

changes in visual function (visual acuity, visual field);
structural measures (retinal nerve fiber layer thickness, OCT);
immune profiling and pharmacokinetics of doxycycline and vector[1][3][4].

The main purpose is to test whether partial epigenetic reprogramming can be applied safely in humans, not yet to prove definitive efficacy[1][3][9].

Target indications: OAG and NAION

Open‑angle glaucoma

Open‑angle glaucoma is the most common form of glaucoma and is characterized by:

chronic or intermittent elevated intraocular pressure (though not always);
progressive degeneration of retinal ganglion cells;
typically irreversible loss of visual field once damage has occurred[1][4].

Current therapies (eye drops, laser, surgery) aim to lower intraocular pressure and slow progression, but they do not restore lost RGCs.
ER‑100 is different in that it attempts to rejuvenate and restore function in existing RGCs, potentially modifying the disease course rather than targeting only a risk factor[1][4][9].

Non‑arteritic anterior ischemic optic neuropathy (NAION)

NAION is often described as an “eye stroke”:
a sudden perfusion failure at the optic nerve head causes acute vision loss in middle‑aged and older adults[3][10].

There is currently no standard treatment that restores vision after NAION; management focuses on risk factors and natural history.
ER‑100 could, in principle:

limit damage by making RGCs more resilient if given early;
promote axon regeneration and recovery in surviving neurons[3][10].

Primate data show protective and restorative effects on retinal function in a NAION‑like model, motivating clinical exploration in humans[10].

Potential benefits of ER‑100

1. A genuinely novel, rejuvenation‑based approach

ER‑100 is the first clinical therapy explicitly aiming at “epigenetic restoration” in neurons:

it does not simply correct a single gene or reduce a risk factor;
it attempts to “turn back the clock” of RGCs to a younger functional state[4][9].

If successful, it could reshape glaucoma management, adding a regenerative layer on top of existing pressure‑lowering treatments[4][9].

2. Time‑controlled expression via doxycycline

The doxycycline‑inducible system provides a strong safety lever:

OSK expression is strictly time‑limited to the 8‑week window;
clinicians can stop doxycycline if issues arise;
this reduces the risk of uncontrolled reprogramming or undesired cell transformation[3][5][9].

3. Favorable target organ: the eye

The eye is a highly accessible organ for gene therapy:

the retina can be imaged with high‑resolution tools (OCT, fundus imaging);
structure and function (visual fields, ERG) are well quantifiable;
the compartment is relatively isolated, limiting systemic spread of the vector[3][4][10].

4. Platform implications beyond ophthalmology

ER‑100 is the first test case of the PER platform, but Life Biosciences is also developing:

ER‑300 and other candidates for liver and metabolic diseases;
small molecules targeting chaperone‑mediated autophagy and other aging pathways[4][6][7].

If ER‑100 shows that partial reprogramming can be delivered safely, similar approaches could be extended to:

other optic neuropathies;
liver disease;
potentially broader age‑related conditions[4][6][7].

Risks, limitations, and open questions

1. Long‑term safety

Despite exclusion of c‑MYC and use of an inducible system, epigenetic reprogramming is a powerful intervention:

large‑scale shifts in gene expression may have unpredictable consequences;
late‑onset effects (cancer, dedifferentiation, progressive dysfunction) might only appear after years[4][9].

This motivates the 5‑year follow‑up built into the trial design[3][4].

2. Immune responses to AAV

AAV vectors can trigger:

neutralizing antibodies;
T‑cell responses;
ocular inflammation.

In a delicate tissue such as the retina, inflammation can worsen vision loss.
The trial therefore includes intensive monitoring of immune and inflammatory endpoints[3][4][10].

3. Patient selection and disease stage

ER‑100 can act only on remaining neurons:

in advanced glaucoma with massive RGC loss, benefit may be limited;
in NAION, time‑to‑treatment could critically influence outcomes[3][10].

Defining optimal therapeutic windows and identifying patients most likely to benefit will be essential research questions.

4. Ethical and societal considerations

ER‑100 also raises broader issues:

treating aging itself as a therapeutic target;
potential non‑therapeutic uses of rejuvenation technologies;
equitable access to complex and potentially expensive therapies.

For now, ER‑100 remains confined to a strictly controlled clinical trial in patients with serious disease, but its implications reach far beyond ophthalmology[4][8][9].

Current status and outlook

As of now, ER‑100:

is in Phase 1 clinical testing in OAG and NAION patients;
is backed by strong preclinical data in mice and non‑human primates;
benefits from an $80 million Series D funding round to support the trial and the PER platform[1][4][6][7].

Initial safety readouts are expected around late 2026, with exploratory efficacy hints possibly emerging later if the trial proceeds smoothly[2][3][4].
Likely next steps include:

larger, controlled Phase 2 trials focusing on efficacy;
exploration of dosage and timing;
combination of ER‑100 with standard glaucoma therapies.

Regardless of outcome, ER‑100 represents a pioneering experiment: the first attempt to use partial epigenetic reprogramming to restore vision in humans[1][4][9].

Sources (selected)

[1] Life Biosciences press release on FDA IND clearance for ER‑100.
[2] Popular science coverage announcing first patient dosing.
[3] ClinicalTrials.gov record NCT07290244 for the ER‑100 Phase 1 trial.
[4] Nature article on FDA approval to test a cellular rejuvenation therapy in humans.
[5] Educational videos/blogs describing the single‑dose + 8‑week doxycycline regimen.
[6] BiopharmaTrend article on Life Biosciences’ $80M Series D financing.
[7] Life Biosciences pipeline page describing PER and ER‑100.
[8] Analyst commentary on the first clinical application of partial reprogramming.
[9] Academic work from the Sinclair lab on OSK and epigenetic reprogramming.
[10] Ophthalmology reports on ER‑100 preclinical results in primate NAION‑like models.